investor at MMC Ventures, added: “There is an urgent need to solve the largest problems in clinical trials: patient recruitment and engagement. This is where Sano’s innovative software platform, which allows them to interact directly with patients, biotech and broader healthcare communities, can be transformational for the future of personalised medicine.”

“It still takes 10 to 15 years for new drugs to reach patients, and many will never make it out of R&D because costs are prohibitive. This funding takes us closer to our mission to build the platform that we, and many others – patients and researchers – wish was available a decade ago. One that will make research much faster, more cost-effective, and a vastly better experience for patients.”

Attempting to change this, the company has developed a software platform that connects patients living with rare and chronic conditions such as Long Covid, multiple sclerosis, Parkinson’s and Alzheimer’s, directly with biotech and pharma companies leading personalised medicine research. Betting big on a market worth $52.4 billion in 2020 and predicted to reach $112.8 billion by 2027, it also offers biotech and pharma clients the ability to power branded portals for participant recruitment and engagement.